Par cleared but Watson liable over Novartis patents

26-05-2015

Par cleared but Watson liable over Novartis patents

360b / Shutterstock.com

A US appeals court has issued a mixed judgment in a patent dispute that saw Novartis file infringement claims against both Watson Pharmaceuticals and Par Pharmaceutical.


Novartis; US Court of Appeals for the Federal Circuit; Watson Pharmaceuticals; rivastigmine; ANDA; US District Court for the District of Delaware; Par Phar

LSIPR